First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors

被引：49

作者：

Bylicki, Olivier ^{[1
]}

Barazzutti, Helene ^{[2
]}

Paleiron, Nicolas ^{[2
]}

Margery, Jacques ^{[1
]}

Assie, Jean-Baptiste ^{[3
]}

Chouaid, Christos ^{[3
]}

机构：

[1] Hop Instruct Armees Percy, Serv Pneumol, 106 Ave Henri Barbusse, F-92140 Clamart, France

[2] Hop Instruct Armees St Anne, Dept Resp Dis, Toulon, France

[3] Ctr Hosp Intercommunal Creteil, Serv Pneumol, 40 Ave Verdun, F-94010 Creteil, France

来源：

BIODRUGS | 2019年 / 33卷 / 02期

关键词：

PACLITAXEL PLUS CARBOPLATIN; RANDOMIZED PHASE-III; OPEN-LABEL; STAGE IV; MAINTENANCE BEVACIZUMAB; PD-L1; EXPRESSION; CHEMOTHERAPY; NIVOLUMAB; THERAPY; PEMBROLIZUMAB;

D O I：

10.1007/s40259-019-00339-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with molecularly targeted therapies, had been based on cytotoxic chemotherapy for a long time. Immunecheckpoint inhibitors (ICIs), notably antibodies directed against programmed cell-death protein-1 (PD-1) and its ligand (PD-L1) have transformed therapeutic standards in thoracic oncology. These ICIs are now the reference second-line treatment and numerous phase III trials have examined their efficacy in treatment-naive patients. First-line pembrolizumab monotherapy was validated for patients with50% of tumor cells expressing PD-L1; pembrolizumab, atezolizumab, and nivolumab have obtained good outcomes in combination with chemotherapy or another immunotherapy. However, in this context, other phase III trials yielded negative findings for nivolumab alone (CheckMate-026) or in combination (MYSTIC trial). Biomarkers, such as PD-L1 and the tumor mutation burden (TMB), enable better selection of patients who should benefit the most from first-line ICI use.

引用

页码：159 / 171

页数：13

共 61 条

[21] Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents [J].

Galluzzi, Lorenzo ;

Buque, Aitziber ;

Kepp, Oliver ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER CELL, 2015, 28 (06) :690-714

[22] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[23] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

[24] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott ;

Rizvi, Naiyer A. ;

Chow, Laura Q. ;

Borghaei, Hossein ;

Brahmer, Julie ;

Ready, Neal ;

Gerber, David E. ;

Shepherd, Frances A. ;

Antonia, Scott ;

Goldman, JonathanW. ;

Juergens, Rosalyn A. ;

Laurie, Scott A. ;

Nathan, Faith E. ;

Shen, Yun ;

Harbison, Christopher T. ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2980-+

[25] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

[26] Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients [J].

Gopalakrishnan, V. ;

Spencer, C. N. ;

Nezi, L. ;

Reuben, A. ;

Andrews, M. C. ;

Karpinets, T. V. ;

Prieto, P. A. ;

Vicente, D. ;

Hoffman, K. ;

Wei, S. C. ;

Cogdill, A. P. ;

Zhao, L. ;

Hudgens, C. W. ;

Hutchinson, D. S. ;

Manzo, T. ;

de Macedo, M. Petaccia ;

Cotechini, T. ;

Kumar, T. ;

Chen, W. S. ;

Reddy, S. M. ;

Sloane, R. Szczepaniak ;

Galloway-Pena, J. ;

Jiang, H. ;

Chen, P. L. ;

Shpall, E. J. ;

Rezvani, K. ;

Alousi, A. M. ;

Chemaly, R. F. ;

Shelburne, S. ;

Vence, L. M. ;

Okhuysen, P. C. ;

Jensen, V. B. ;

Swennes, A. G. ;

McAllister, F. ;

Sanchez, E. Marcelo Riquelme ;

Zhang, Y. ;

Le Chatelier, E. ;

Zitvogel, L. ;

Pons, N. ;

Austin-Breneman, J. L. ;

Haydu, L. E. ;

Burton, E. M. ;

Gardner, J. M. ;

Sirmans, E. ;

Hu, J. ;

Lazar, A. J. ;

Tsujikawa, T. ;

Diab, A. ;

Tawbi, H. ;

Glitza, I. C. .

SCIENCE, 2018, 359 (6371) :97-103

[27] Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Hanna, Nasser ;

Johnson, David ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Giaccone, Giuseppe ;

Hesketh, Paul J. ;

Jaiyesimi, Ishmael ;

Leighl, Natasha B. ;

Riely, Gregory J. ;

Schiller, Joan H. ;

Schneider, Bryan J. ;

Smith, Thomas J. ;

Tashbar, Joan ;

Biermann, William A. ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3484-+

[28] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[29] Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer [J].

Hellmann, Matthew D. ;

Callahan, Margaret K. ;

Awad, Mark M. ;

Calvo, Emiliano ;

Ascierto, Paolo A. ;

Atmaca, Akin ;

Rizvi, Naiyer A. ;

Hirsch, Fred R. ;

Selvaggi, Giovanni ;

Szustakowski, Joseph D. ;

Sasson, Ariella ;

Golhar, Ryan ;

Vitazka, Patrik ;

Chang, Han ;

Geese, William J. ;

Antonia, Scott J. .

CANCER CELL, 2018, 33 (05) :853-+

[30]

Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]

← 1 2 3 4 5 6 7 →